# Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis

> **NCT06510283** · PHASE2 · RECRUITING · sponsor: **Beijing Tongren Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Anti-N-Methyl-D-Aspartate Receptor Encephalitis

## Interventions

- **DRUG:** Taitacept

## Key facts

- **NCT ID:** NCT06510283
- **Lead sponsor:** Beijing Tongren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2027-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06510283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06510283, "Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06510283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*